{
    "clinical_study": {
        "@rank": "60585", 
        "acronym": "SMART", 
        "arm_group": [
            {
                "arm_group_label": "Golimumab Prefilled Syringe", 
                "arm_group_type": "Experimental", 
                "description": "Golimumab 50 mg supplied in a prefilled syringe administered four times (two times by the treating physician and 2 times by the participant under the supervision of the treating physician)."
            }, 
            {
                "arm_group_label": "Golimumab Smartject\u2122 Device", 
                "arm_group_type": "Experimental", 
                "description": "Golimumab 50 mg supplied in an auto-injector device administered four times (two times bythe treating physician and 2 times by the participant under the supervision of the treating physician)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to determine whether ulcerative colitis participants prefer delivery\n      of golimumab via a prefilled syringe or the Smartject\u2122 device."
        }, 
        "brief_title": "Preference for a Prefilled Syringe or Smartject\u2122 Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer", 
                "Stress, Psychological"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Anti-tumor necrosis factor (anti-TNF) naive participants with a diagnosis of\n             moderate-to-severe ulcerative colitis.\n\n          -  Mayo clinic score >= 6, including endoscopic subscore >=2;\n\n          -  Previous conventional therapy for a period of at least 3 months with aminosalicylates\n             and at least 3 months with corticosteroids or  6-mercaptopurine (6-MP) or\n             azathioprine (AZA), unless the participant is intolerant to, or has contraindications\n             to these treatments;\n\n          -  Anti-TNF experienced participants with an established diagnosis of moderate-to-severe\n             ulcerative colitis, either not responding or partially responding to treatment with\n             Remicade (infliximab). The participant must also meet the following criteria prior to\n             initiating first-line anti-TNF treatment: Mayo score \u2265 6, including an endoscopic\n             subscore \u2265 2; and previous conventional therapy of at least 3 months with\n             aminosalicylates and at least 3 months with corticosteroids or 6-mercaptopurine\n             (6-MP) or azathioprine (AZA), unless the participant is intolerant to or have medical\n             contraindications for such therapies (should be documented);\n\n          -  Sexually active women of child-bearing potential must agree to use a medically\n             accepted method of contraception while receiving study drug and for 6 months after\n             the stop of study drug;\n\n        Exclusion Criteria:\n\n          -  Has a history of prior self-injection for any reason;\n\n          -  Has concomitant use of other biologic agents;\n\n          -  Has active tuberculosis (TB) within 12 months prior to the first injection or  has\n             suspected latent TB as indicated by a positive tuberculin skin test.\n\n          -  Has an active clinical non-tuberculous mycobacterial infection or opportunistic\n             infection within 6 months prior to the first injection;\n\n          -  Has had an active infection and/or serious infection within 6 months prior to the\n             first study drug administration;\n\n          -  Has had a live viral or bacterial vaccination within 3 months prior to the first\n             study injection or Bacillus Calmette-Guerin vaccination within 12 months prior to the\n             first study drug injection;\n\n          -  Has evidence of heart failure of New York Heart Association class 3-4;\n\n          -  Has a history of demyelinating disease such as multiple sclerosis or optic neuritis;\n\n          -  Has a history of systemic lupus erythematosus;\n\n          -  Has a history of lymphoproliferative disease, or any unknown malignancy or history of\n             malignancy within the prior 5 years, with the exception of non-melanoma skin cancer\n             that has been treated with no evidence of recurrence;\n\n          -  Has had an active hepatitis B infection;\n\n          -  Has an allergy or sensitivity to golimumab or its excipients;\n\n          -  Is pregnant or breast feeding;\n\n          -  Is sensitive to latex."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155335", 
            "org_study_id": "8259-027", 
            "secondary_id": "2014-000656-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Golimumab Prefilled Syringe", 
                "description": "Golimumab 50 mg via subcutaneous injection.", 
                "intervention_name": "Golimumab Prefilled Syringe", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SIMPONI", 
                    "MK-8259-027"
                ]
            }, 
            {
                "arm_group_label": "Golimumab Smartject\u2122 Device", 
                "description": "Golimumab 50 mg via subcutaneous injection.", 
                "intervention_name": "Golimumab Smartject\u2122 Device", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SIMPONI", 
                    "MK-8259-027"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "number_of_arms": "2", 
        "official_title": "Preference for a Prefilled Syringe or Smartject\u2122 Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis", 
        "overall_contact": {
            "email": "ClinicalTrialsDisclosure@merck.com", 
            "last_name": "Toll-Free Number", 
            "phone": "888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants Who Prefer Prefilled Syringe, Smartject\u2122 Device, or are Undecided", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155335"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}